GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa
The company's Blujepa is the first in a new class of oral antibiotics for UTIs in nearly 30 years and was designed to fight the common condition with a lower potential for antimicrobial resistance
The company's Blujepa is the first in a new class of oral antibiotics for UTIs in nearly 30 years and was designed to fight the common condition with a lower potential for antimicrobial resistance
